Close

Anti-Nef TCR-NK Cells (XS-0623-ZP71)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The genetically modified anti-Nef TCR-NK cell is designed to target to the specific epitope-HLA complex. The TCR-NK is expected to show antigen-specific cytotoxicity against Nef antigen via the introduced TCR were successfully produced.

  Add to Cart

Specifications

  • Cell Type
  • TCR-NK
  • Host Cell Type
  • Primary NK cells

TCR Design

  • Target
  • Nef
  • Common Name
  • Nef
  • Target Species
  • HIV-1
  • TCR-Host Animal
  • Human
  • Vector Name
  • pCDTCR1
  • Vector length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
Sub CAT. HLA TCR Clone Epitope  
XS-0623-ZP71-SUB1 HLA-A24 H27-14 RYPLTFGWCF
XS-0623-ZP71-SUB2 HLA-A24 PDWQNYTPGPG
XS-0623-ZP71-SUB3 HLA-B0702 RPMTYKGAL
XS-0623-ZP71-SUB4 HLA-A24 C1-28 RYPLTFGWCF
XS-0623-ZP71-SUB5 HLA-A24 T36-5 RFPLTFGWCF
XS-0623-ZP71-SUB6 HLA-A*24:02 CB-C198 RYPLTFGWCF
XS-0623-ZP71-SUB7 HLA-A*24:02 CB-C199 RYPLTFGWCF
XS-0623-ZP71-SUB8 HLA-A*24:02 CB-C200 RYPLTFGWCF
XS-0623-ZP71-SUB9 HLA-A*24:02 CB-C201 RYPLTFGWCF
XS-0623-ZP71-SUB10 HLA-A*24:02 CB-C202 RYPLTFGWCF
XS-0623-ZP71-SUB11 HLA-A*24:02 CB-C203 RYPLTFGWCF
XS-0623-ZP71-SUB12 HLA-A*24:02 CB-C204 RYPLTFGWCF
XS-0623-ZP71-SUB13 HLA-A*24:02 CB-C205 RYPLTFGWCF
XS-0623-ZP71-SUB14 HLA-A*24:02 CB-C206 RYPLTFGWCF
XS-0623-ZP71-SUB15 HLA-A*24:02 CB-C207 RYPLTFGWCF
XS-0623-ZP71-SUB16 HLA-A*24:02 CB-C208 RYPLTFGWCF
XS-0623-ZP71-SUB17 HLA-A*24:02 CB-C209 RYPLTFGWCF
XS-0623-ZP71-SUB18 HLA-A*24:02 CB-C210 RYPLTFGWCF
XS-0623-ZP71-SUB19 HLA-A*24:02 CB-C211 RYPLTFGWCF
XS-0623-ZP71-SUB20 HLA-A*24:02 CB-C212 RYPLTFGWCF
XS-0623-ZP71-SUB21 HLA-A*24:02 CB-C213 RYPLTFGWCF
XS-0623-ZP71-SUB22 HLA-A*24:02 CB-C214 RYPLTFGWCF
XS-0623-ZP71-SUB23 HLA-A*24:02 CB-C215 RYPLTFGWCF
XS-0623-ZP71-SUB24 HLA-A*24:02 CB-C216 RYPLTFGWCF
XS-0623-ZP71-SUB25 HLA-A*24:02 CB-C217 RYPLTFGWCF
XS-0623-ZP71-SUB26 HLA-A*24:02 CB-C218 RYPLTFGWCF
XS-0623-ZP71-SUB27 HLA-A*24:02 CB-C219 RYPLTFGWCF
XS-0623-ZP71-SUB28 HLA-A*24:02 CB-C220 RYPLTFGWCF
XS-0623-ZP71-SUB29 HLA-A*24:02 CB-C221 RYPLTFGWCF
XS-0623-ZP71-SUB30 HLA-A*24:02 CB-C222 RYPLTFGWCF
XS-0623-ZP71-SUB31 HLA-A*24:02 CB-C223 RYPLTFGWCF
XS-0623-ZP71-SUB32 HLA-A*24:02 CB-C224 RYPLTFGWCF
XS-0623-ZP71-SUB33 HLA-A*24:02 CB-C225 RYPLTFGWCF
XS-0623-ZP71-SUB34 HLA-A*24:02 CB-C226 RYPLTFGW
XS-0623-ZP71-SUB35 HLA-A*24:02 CB-C227 RYPLTFGW
XS-0623-ZP71-SUB36 HLA-A*24:02 CB-C228 RYPLTFGW
XS-0623-ZP71-SUB37 HLA-A*24:02 CB-C229 RYPLTFGW
XS-0623-ZP71-SUB38 HLA-A*24:02 CB-C230 RYPLTFGW
XS-0623-ZP71-SUB39 HLA-A*24:02 CB-C231 RYPLTFGW
XS-0623-ZP71-SUB40 HLA-A*24:02 CB-C232 RYPLTFGW

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-Nef TCR-NK Cells (XS-0623-ZP71). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.